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More pumps—more questions
To the Editor:
We would like to congratulate Wilhelm
and colleagues1 on their outstanding results
concerning long-term survival after the im-
plantation of axial flow left ventricular as-
sist devices (LVADs). Since the worldwide
first implantation of the axial flow pump in
our institution on November 13, 1998,2 fol-
lowed by implantations in Vienna 1 week
later,3 these pumps have increasingly
gained acceptance. Long-term LVAD sup-
port not only enables patients to be bridged
to heart transplantation or recovery but also
opens up the opportunity to prolong high-
quality life for nontransplant candidates.
The article presented also shows that long-
term nonpulsatile or less-pulsatile blood
flow is not detrimental for the function of
the end organs. Our experience with 44
patients who were supported with rotary
blood pumps for more than 200 days ac-
cords with the results presented by the au-
thors. However, good long-term results can
also be achieved with pulsatile systems. Of
a total of 110 patients supported with an
LVAD for longer than 200 days in our
institution, 66 had pulsatile devices. Of
these, 3 patients were supported for more
than 4 years with the Novacor LVAS and 2
with the BerlinHeart Excor.4
During long-term support, appropriate
anticoagulation plays a key role for the
survival and complication rates. As antico-
agulative medication with the rotary
pumps, we now administer phenprocou-
mon with a target international normalized
ratio of 2.5, aspirin, and, in patients sup-
ported with axial flow pumps, additional
clopidogrel according to platelet aggrega-
tion tests, taking polymorphism of the
platelet GP IIb/IIIa receptors into consid-
eration.5 In our opinion the aspirin dose
should not exceed 100 mg/d.
We would be interested in the authors’
current anticoagulation protocols and whether
they used different regimens in patients
with different rotary blood pumps. Second,
based on the experience gained in Münster,
are there any preferences of pump type for
destination therapy?
E. V. Potapov, MD
R. Hetzer, MD, PhD
Deutsches Herzzentrum Berlin
Augustenburger Platz 1
13353 Berlin
Germany
E-mail: potapov@dhzb.de
References
1. Wilhelm MJ, Hammel D, Schmid C, Rhode
A, Kaan T, Rothenburger M, et al. Long-term
support of 9 patients with the DeBakey VAD
for more than 200 days. J Thorac Cardiovasc
Surg. 2005;130:1122-9.
2. Potapov EV, Loebe M, Nasseri BA, Sinawski
H, Koster A, Kuppe H, et al. Pulsatile flow in
patients with a novel nonpulsatile implant-
able ventricular assist device. Circulation.
2000;102(suppl III):III183-7.
3. Wieselthaler GM, Schima H, Lassnigg A,
Pacher R, Ovsenk T, Laufer G, et al. The
DeBakey VAD axial flow pump: first clinical
experience with a new generation of implant-
able, nonpulsatile blood pumps for long-term
support prior to transplantation. Wien Klin
Wochenschr. 1999;111:629-35.
4. Potapov E, Jurmann M, Drews T, Pasic M,
Loebe M, Weng Y, et al. Patients supported
for over four years with left ventricular assist
devices. Eur J Heart Fail. 2006 In press.
5. Potapov EV, Ignatenko S, Nasseri BA, Loebe
M, Harke C, Bettmann M, et al. Clinical
significance of PlA polymorphism of platelet
GP IIb/IIIa receptors during long-term VAD
support. Ann Thorac Surg. 2004;77:869-74.
doi:10.1016/j.jtcvs.2005.12.071
Reply to the Editor:
Left ventricular assist device (LVAD) sup-
port was originally used to bridge high risk
patients to heart transplantation.1 After in-
creased experience with this therapy
showed that the failing native heart may
have the potential to recover, LVAD ther-
apy provided the option of weaning se-
lected patients from mechanical support as
an alternative to transplantation.2 As tech-
nology made further progress, the duration
of support has increased markedly and
paved the way for destination therapy.
Device selection, however, in particular
for long-term support, still remains an un-
resolved question. Most centers have expe-
rience with one or two types of devices.
Devices are selected on the basis of per-
sonal experience. As long as people are
satisfied with the devices they are using,
they do not see a reason to change to other
systems. Only centers that handle large
numbers of patients use a variety of de-
vices, which offers them the opportunity to
compare systems. Prospective randomized
studies to evaluate different devices for
different indications have not yet been
performed.
It is of foremost importance that
LVADs meet the criteria of long-term reli-
ability and excellent quality of life in ad-
dition to the standard requirements of low
frequency of infection and thromboembo-
lism. The intracorporeal pulsatile devices
such as the Novacor LVAS and the Heart-
Mate I have demonstrated reliability for
long-term support.3,4 Extracorporeal pulsa-
tile devices such as the Thoratec LVAD
and the Berlin Heart Excor also have sup-
ported patients over the long term.5,6 The
introduction of axial-flow pumps revolu-
tionized mechanical circulatory support.
Pump size was markedly reduced, which
facilitated the implantation procedure.
Bleeding and infectious complications be-
came less frequent. Because axial-flow
pumps have not been on the market as long
as pulsatile devices, their long-term reli-
ability still has to be proved. Some patients
were supported for more than 1 year with
the DeBakey VAD, the Jarvik 2000, or the
Berlin Heart Incor, respectively.7-9 In par-
ticular, the Berlin Heart Incor promises
good long-term performance because of the
magnetic suspension of its impeller, which
provides virtually unlimited durability. The
longest support period with this device is
about 3 years. The design of axial-flow
pumps renders the exchange of single parts
less invasive than is required for larger
pulsatile devices.
Axial-flow pumps appear to provide a
better quality of life than pulsatile devices.
They are much smaller than intracorporeal
pulsatile pumps, which makes them easier
to implant in the pericardium. There is no
need for placement in the abdominal wall
or in the abdomen, which may cause gas-
trointestinal and digestive complications.
In addition, the axial-flow pumps run si-
lently, whereas the clatter of pulsatile de-
vices accompanies the patient and his en-
vironment day and night. Extracorporeal
pulsatile systems are associated with an
additional aesthetic and psychological dis-
advantage. The pump chambers, which are
located permanently outside the body, re-
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mind the patient of his disease, and people
immediately recognize the patient as ill. In
addition, personal mobility is limited be-
cause of the extracorporeal driving unit.
All of these factors limit quality of life.
The greater power of pulsatile devices
is often considered an advantage compared
with axial-flow pumps. However, experi-
ence shows that a flow of 3 to 5 L/min,
which is easily provided by axial-flow de-
vices, is sufficient support for daily activi-
ties. The continuous flow is well tolerated.
This fact may be, at least in part, explained
by the flow characteristics. Patients on ax-
ial-flow pumps have a less pulsatile flow
pattern because the activity of the native
heart at rest transmits pulse waves through
the pump. This activity is obviously suffi-
cient to reestablish and maintain normal
organ function.
Taking all of these factors into account,
the authors prefer axial-flow devices for
long-term support. For destination therapy,
the authors currently use the Berlin Heart
Incor, which is being evaluated for this
indication in the INDESTINY trial. The
management of anticoagulation and plate-
let inhibition in patients with axial-flow
devices still remains an unsolved problem.
Experience with the DeBakey VAD, which
was the first axial-flow pump on the mar-
ket, showed that, in such pumps, platelet
inhibition in addition to anticoagulation is
even more important than in pulsatile de-
vices. In our own experience with the De-
Bakey VAD, administration of clopidogrel
(75 mg) in addition to aspirin (300 mg) and
dipyridamol (75 mg) as well as intensifica-
tion of oral anticoagulation (INR 3.5 to 4.5)
reduces the frequency of thromboembolic
events.7 In patients with the Berlin Heart
Incor, the regimen was modified. Antico-
agulation is titrated at an INR of 2.0 to 3.0,
and platelet inhibition consists of aspirin
(100 mg) and clopidogrel (75 mg). Anti-
platelet therapy is individually guided by
different platelet function tests.
We do not yet have the optimal pump
for destination therapy. We need pumps
with better flow characteristics and fluid
dynamics that cause less damage to plate-
lets and reduce the risk of thrombus forma-
tion. It will be interesting to see if the
implantable centrifugal devices that will
soon be on the market have an advantage in
this respect. The pumps are required to run
reliably and service-free for many years,
and their design should allow exchange of
worn parts in a minimally invasive inter-
vention. Completely implantable devices
with controller and energy supply inside
the body, which are currently in develop-
ment, will further increase quality of life
and reduce the risk of infection.
Markus J. Wilhelm, MD
Christof Schmid, MD
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Is off-pump therapy really the right
choice in urgent coronary grafting?
To the Editor:
I read with interest the article by Stamou
and colleagues,1 wherein they compare the
early outcomes in nonelective myocardial
revascularization in patients undergoing
on-pump and off-pump bypass. However,
it is arguable as to whether the conclusions
drawn from this report will have an endear-
ing and widespread influence on this issue.
First, even though recent studies are
increasingly documenting better outcomes
among patients undergoing off-pump pro-
cedures, a number of well-designed trials
in the past and present (including both elec-
tive and urgent cases) have yielded con-
flicting results in this regard. Also, it is
unclear as to why the urgent cases should
be handled on a separate basis because the
inflammatory effects associated with car-
diopulmonary bypass are likely to be the
same in both elective and nonelective sce-
narios, and the greater risks faced by these
patients might solely be a result of their
emergency nature of presentation, not hav-
ing anything to do with cardiopulmonary
bypass use.
Second, the authors state the superiority
of off-pump surgery in urgent cases on the
basis of the former decreasing the rate of
intra-aortic balloon pump placement and
renal failure. As regards intra-aortic bal-
loon pump placement, studies have shown
that off-pump surgery reduces the need for
its use in elective cases. However, even as
this evidence might tilt the balance toward
off-pump surgery in elective cases, the ar-
gument is unlikely to have a significant
influence on decision making in urgent
cases, in which hemodynamic instability is
often an issue and balloon pump placement
is frequently mandated on purely clinical
grounds. Also, although cardiopulmonary
bypass is shown to have a detrimental in-
fluence on renal function in this report,
recent propensity score study with univar-
iate and multivariate analysis shows that
off-pump grafting itself might not have any
influence in reducing the rate of postoper-
ative renal dysfunction in patients at risk
for nephrologic compromise, raising
doubts regarding the validity of using the
kidney-sparing argument in support of off-
pump surgery.2
Finally, before off-pump surgery is
adapted as the primary approach in urgent
coronary revascularization, it must be kept
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